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a representative Italian cohort of free-living nona-
genarians. to assess the association between specific 
peripheral inflammation markers derived from white 
blood cell counts, and the diagnosis of dementia. All 
the variables of interest were reported for 411 sub-
jects (110 males and 301 females) out of 475 enrolled 
in the study. Anamnestic dementia diagnosis was 
obtained from clinical certificate and confirmed by a 
Abstract Immunosenescence, vascular aging, and 
brain aging, all characterized by elevated levels of 
inflammatory markers, are thought to share a com-
mon pathogenetic pathway: inflamm-aging. Ret-
rospective cross-sectional analysis was conducted 
using data from the Mugello study (Tuscany, Italy), 
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General Practitioner, whereas leukocyte ratios were 
directly calculated from white blood cell counts. 
Body mass index and comorbidities were consid-
ered potential confounders. Diagnosis of any type 
dementia was certified in 73 cases (17.8%). Subjects 
affected by dementia were older, more frequently 
reported a previous stroke, had lower body mass 
index, and lower Mini-Mental-State-Examination 
score. Moreover, they had a higher lymphocyte count 
and lymphocyte-to-monocyte ratio compared to the 
non-demented nonagenarians. We found that higher 
levels of lymphocyte counts are cross-sectionally 
associated with a clinical diagnosis of dementia. Fur-
thermore, lymphocyte-to-monocyte ratio is directly 
associated with any type of dementia, independently 
of age, sex, lymphocyte count, and comorbidities. 
Lymphocyte-to-monocyte ratio may be considered 
a marker of immunological changes in the brain of 
dementia patients; moreover, it is low-cost, and easily 
available, thus enabling comparisons among differ-
ent studies and populations, although the timeline and 
the extent of lymphocyte-to-monocyte ratio role in 
dementia development must be further investigated.
Keywords Inflamm-aging · Immunosenescence · 
Neuroinflammation · Lymphocyte count · 
Lymphocyte-to-monocyte-ratio · Dementia
Introduction
Dementia is a chronic, progressive syndrome affect-
ing both cognitive and functional abilities, repre-
senting one of the major causes of disability and 
dependency among older people. The incidence of 
dementia increases exponentially with age, before 
the age of 90 years, but few data are available for the 
oldest-old and for centenarians [1]. The aging pro-
cess is associated with chronic low-grade inflamma-
tion, that is present not only in peripheral tissues, but 
involves also the brain [2]. Converging evidence sup-
ports the hypothesis that both central and peripheral 
inflammation play a pivotal role in the pathogenesis 
of dementia [3]. The central nervous system (CNS) 
inflammation process has polyhedric manifestations, 
occurring in the continuum of the different stages of 
dementia [4]; moreover, different forms of dementia 
might share inflammation as an etiopathological trig-
ger and a common pathway [5]. In older individuals, 
due to multiple systemic inflammatory events [6], 
and in the earliest silent dementia phase, in response 
to intraneuronal accumulation of oligomeric pep-
tides, neurotoxic cytokines are released [7]: in this 
inflammatory scenario, microglia are activated [8], 
driving further proinflammatory conditions which in 
turn induce an anti-inflammatory response [9]. The 
progression of these processes culminates with the 
imbalance between adaptive/innate immune response, 
CNS invasion by peripheral monocytes [10], lympho-
cyte proliferation [7], and hyperactivation of micro-
glial phagocytic cells [2]. Because of the association 
between dementia pathogenesis and the immune sys-
tem, several studies on immune cells as biological 
markers are emerging [11]. The recent COVID-19 
pandemic has renewed the interest in leukocyte count-
derived indexes, which are easily available at no extra 
cost, and represent possible markers of inflammation 
with predictive value for disease outcome, not only in 
the elderly. The leukocytes derived ratio, as a com-
bined inflammatory biomarker, integrates information 
from innate and adaptive immunity [5]. It avoids the 
disadvantage of an absolute value of a single leuko-
cyte subtype, which may be affected by infection or 
dehydration, and has higher clinical significance than 
the other independent inflammatory biomarkers [12]. 
In the context of dementia, one case–control study 
has been published, reporting that leukocyte ratios 
can discriminate patients with dementia from con-
trols [13]. In a free living “young-old” population 
(mean age 61 years), the Rotterdam study reported an 
increase of Neutrophils and contextually a decrease of 
lymphocyte absolute numbers, with dementia patients 
showing a higher activation of the innate immune 
system, measured by different leukocytes ratios, com-
pared to controls [14]. To date, these associations 
have not been explored within a representative oldest-
old population sample.
The aim of the present study is to evaluate the 
association of routinely available, specific peripheral 
inflammation markers, with a diagnosis of demen-
tia, in a cohort of community-dwelling oldest-old 
participants.
Materials and methods
The design of the Mugello study has been described 
in detail elsewhere [15]. Briefly, the project was 
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designed and conducted by the Department of Exper-
imental and Clinical Medicine, University of Flor-
ence, Italy, and by the Don Carlo Gnocchi Foundation 
(Florence, Italy). The study was designed as a cross-
sectional survey of subjects aged 90 years and over, 
living in the Mugello area, a valley spread north-east 
of Florence, in Tuscany, and data were collected in 
2009.
Samples
In this retrospective study, 475 nonagenarians (130 
men and 345 women, age range 90–105 years) were 
enrolled, representing approximately 65% of those 
nonagenerians living in the Mugello area; 411 par-
ticipants who had all the variables of interest were 
included in this analysis. There were no exclusion 
criteria. The study protocol, which complied with the 
principles of the Declaration of Helsinki on clinical 
research involving human subjects, was approved by 
the Institutional Review Board. All participants, or 
their proxies, signed the informed consent form to 
participate to the study.
Home interview and diagnoses of pathological 
conditions
A trained interviewer investigated family, medical, 
and medication history. Past and recent medical his-
tory was recorded using a semi-structured question-
naire [16].
Comprehensive geriatric assessment
Specific geriatric items, such as functional inde-
pendence, physical activity level, quality of life, 
global cognition, mood, sleep quality, and falls, were 
addressed. The interview was followed by a general 
physical and clinical examination.
Blood collection
After the clinical assessment, a nurse collected fast-
ing blood samples for routine and other selected labo-
ratory tests. Serum and plasma aliquots were also 
stored at − 80° for future investigation.
Laboratory tests
At the enrollment (2009), several laboratory param-
eters were assessed. Serum levels of Thyroid Stim-
ulating Hormone (TSH) were measured using an 
enzyme-linked immunosorbent assay (ELISA), 
with the WHO First International Reference Stand-
ard, and a sensitivity of 0.08 μg/ml. Albumin, and 
α2-globulin were measured using an agarose gel 
electrophoresis technique (Hydragel Protein(E) 
15/30 and HydraPLUS, Sebia, Issy-les-Moulineaux, 
France). The C-reactive protein (CRP) assay was 
performed using an immunoturbidimetric method 
with a commercial kit (Roche Diagnostics, GmbH, 
Mannheim, Germany) and a Roche Modular P 
Chemistry Analyzer (Roche Diagnostics, GmbH, 
Mannheim, Germany), with a sensitivity of 3  µg/
mL; intra-assay coefficient of variability (CVs) for 
three concentrations were 1.3%, 1.0%, and 0.6%; 
inter-assay CVs for three concentrations were 6.0%, 
2.9%, and 1.3%. Hematological parameters studied 
were hemoglobin, hematocrit, total white blood cell 
(WBC), red blood cell (RBC), and platelet (PLT) 
counts, and the WBC differential count; they were 
measured using the hematology analyzer Sysmex 
XT-1800 (Sysmex, Inc., Mundelein, IL). The fol-
lowing leukocyte-derived indexes were evaluated 
platelet (P)-to-lymphocytes (L) ratio (PLR) [17], 
the neutrophil (N)-to-lymphocyte ratio (NLR) [18], 
the lymphocyte-to-monocyte (M) ratio (LMR) [19], 
and the systemic immune-inflammation index (SII) 
obtained by multiplying the number of P by that of 
M, and the product divided by the number of L [20].
Body mass index (BMI) was calculated as weight 
(kg)/height squared  (m2), and participants were clas-
sified as overweight/obese if their BMI was above 25.
Statistical analysis
Continuous variables were reported as mean and 
standard deviation (SD), whereas dichotomous 
variables were reported as number and percentages. 
Participants were divided into two groups according 
to the presence/absence of a clinical diagnosis of 
any type of dementia.
Differences between the two groups were evalu-
ated by analysis of variance and chi-square test, for 
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continuous and categorical variables, respectively. 
Additional analyses with adjustment for age and 
sex were also reported, since gender dimorphism 
and age effect could interfere with dependent as 
with independent variables. To assess the associa-
tion between any type of dementia with leukocyte-
derived indexes, several different logistic regression 
models were analyzed. Cognitive status (dementia/
non-dementia) was assumed as the dependent vari-
able, and the analysis was carried out stratifying 
for the conditions independently associated with 
dementia at univariate analysis, adjusting for age, 
sex, and lymphocyte count. Results were reported 
as odds ratio (OR) and 95% confidence intervals 
(95%CI). All statistical analyses were performed 
using SAS software rel.9.4.
Results
Four hundred and eleven subjects were included in 
the study: 301 (73.2%) were female; the mean age 
(± SD) of the sample was 93.01 ± 3.17 years. Demen-
tia of any type was clinically certified in 73 cases 
(17.8%). Those subjects were older (94.06 ± 3.66 
vs 92.81 ± 3.14  years, p value < 0.001), mostly 
female (79.5%), with lower BMI (23.86 ± 4.50 vs 
25.41 ± 4.54, p value = 0.01) and lower MMSE score 
(7.05 ± 7.87 vs 21.55 ± 7.91, p value < 0.001). In the 
non-dementia group, on the contrary, albumin con-
centration was higher (56.52 ± 4.64 vs 54.90 ± 4.59, 
p value = 0.02). C-Reactive Protein, α2-globulin, 
and TSH level did not differ between the groups 
(Table  1). Among hematological parameters, lym-
phocyte count was higher in the dementia-group 
compared to the non-dementia-group (2.04 ± 1.24 
vs 1.75 ± 0.72; p value = 0.006); no differences were 
found in all other markers (RBC, WBC, monocytes, 
platelets, hemoglobin, and hematocrit), adjusting 
analysis for age and sex between the two study groups 
(Table  1). The subjects reporting a clinical diagno-
sis of dementia showed higher LMR (4.85 ± 3.00 vs 
3.83 ± 1.85; p value < 0.001) compared to the oth-
ers. For the other leukocyte-derived ratios, namely, 
NLR, PLR, and SII, no differences were observed (p 
value = 0.14; p value = 0.08; p value = 0.14; respec-
tively) (Table 1). Subjects with a diagnosis of demen-
tia showed a higher prevalence of previous stroke 
(30.1% vs 17.5%, p2 = 0.007), and a lower prevalence 
of hypertension (42.5% vs 59.8%, p2 = 0.003), but no 
Table 1  Demographic, 
anthropometric, and 
laboratory parameters, 
reported according to 
certified clinical diagnosis 
of any type dementia; 
p value1 = unadjusted 
p value; p value2 = sex 
and age-adjusted p value. 





lymphocyte ratio; LMR, 
lymphocyte-to-monocyte 
ratio; SII, systemic immune-
inflammation index
Variable No dementia Dementia p value1 p value2
338 73
Age (yy) 92.81 ± 3.14 94.06 ± 3.66  < 0.001
Sex female 243 (71.9) 58 (79.5) 0.19
Education (yy) 4.37 ± 2.74 3.86 ± 1.91 0.10 0.42
BMI 25.41 ± 4.54 23.86 ± 4.50 0.005 0.01
MMSE score (0–30) 21.55 ± 7.91 7.05 ± 7.87  < 0.001  < 0.001
Neutrophils (×  10^3/μl) 3.96 ± 2.49 3.91 ± 1.55 0.87 0.88
Lymphocytes (×  10^3/μl) 1.75 ± 0.72 2.04 ± 1.24 0.007 0.006
Monocytes (×  10^3/μl) 0.50 ± 0.19 0.45 ± 0.16 0.06 0.12
Platelets (×  10^3/μl) 216.02 ± 87.11 215.42 ± 64.70 0.96 0.92
Hemoglobin (g/dl) 12.95 ± 1.54 12.71 ± 1.47 0.22 0.41
Hematocrit (%) 39.10 ± 4.79 37.65 ± 6.82 0.03 0.08
C-reactive protein (mg/dl) 1.016 ± 2.47 1.03 ± 1.76 0.97 0.84
Alpha-2-globulins (%) 12.01 ± 1.84 11.83 ± 2.14 0.45 0.21
Albumin (%) 56.52 ± 4.64 54.90 ± 4.59 0.007 0.02
TSH (μUI/mL) 2.15 ± 5.76 1.99 ± 2.32 0.82 0.65
NLR 2.65 ± 2.65 2.20 ± 1.03 0.15 0.14
PLR 139.80 ± 78.17 122.17 ± 50.24 0.07 0.08
LMR 3.83 ± 1.85 4.85 ± 3.00  < 0.001  < 0.001
SII 570.35 ± 537.38 474.12 ± 272.37 0.14 0.14
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differences in the other major clinical diagnoses con-
sidered (Table 2). No multiplicative effect was dem-
onstrated for the interaction of stroke, hypertension, 
and BMI in the association with dementia (data not 
shown). In the logistic regression model analysis, 
LMR was directly associated with any type demen-
tia (OR = 1.22 95%CI: 1.06–1.42; p value = 0.006) 
independently from age, sex, absolute lymphocyte 
number, hypertension, stroke, and BMI. Interest-
ingly, age and sex did not exert a significant con-
founding effect on the association, whereas stroke 
(p value = 0.03), hypertension (p value = 0.01), and 
BMI (p value = 0.04) were independently associated 
with dementia. Moreover, no significant interaction 
between dependent variables was found. Therefore, 
to better define the role of those diseases in the asso-
ciation with dementia, we carried out different strat-
ified-analyses for the three clinical conditions. The 
associations found are shown in Table 3. In subjects 
without stroke, LMR was associated with dementia 
(OR = 1.02; 95%CI:1.01–1.03; p value = 0.003), but in 
contrast, the association was no longer present in sub-
jects with a history of stroke (p value = 0.38). Obe-
sity (BMI > 25) overlapped the trend found for stroke, 
namely, LMR was associated in subjects with a lower 
BMI (OR = 1.04; 95%CI:1.02–1.06; p value < 0.001), 
whereas in overweight/obese-subjects (BMI > 25), no 
association could be found (p value = 0.07). The pres-
ence or absence of hypertension did not modify the 
strength of the association between LMR and demen-
tia (OR = 1.03;95%CI:1.00–1.05; p value = 0.04, and 
OR = 1.02;95%CI:1.01–1.03; p value = 0.008, respec-
tively). For these three clinical conditions, no medi-
ation-effect in the association between leukocyte-
derived markers and dementia was detected.
We assessed the differences in the lymphocytes 
and monocyte absolute counts, and in the LMR, 
according to dementia and stroke. In subjects report-
ing only dementia, we found a higher lymphocyte 
absolute count (p value = 0.004), lower monocyte 
absolute count (p value < 0.001), and consequently 
higher LMR (p value < 0.001), compared to subjects 
who did not have dementia nor stroke. Moreover, 
in subjects reporting both diseases (dementia and 
stroke), and in those reporting only stroke, monocyte 
numbers were lower compared to those who had nei-
ther dementia nor stroke (Fig. 1).
Discussion
In this cross-sectional population study of nonagenar-
ians, representative of the Italian population of this 
age, we found that a marker of imbalance between 
innate and adaptive immunity (namely LMR) is 
Table 2  Distribution 
of main comorbidity 
diagnosis according to 
certified clinical diagnosis 
of any type dementia; p 
value1 = unadjusted p value; 
p value2 = sex and age-
adjusted p value
No dementia dementia p value1 p value2
338 73
Acute myocardial infarction 46 (13.6) 8 (11.0) 0.54 0.89
Congestive heart failure 74 (21.9) 12 (16.4) 0.30 0.34
Peripheral artery disease 60 (17.8) 10 (13.7) 0.40 0.32
Hypertension 202 (59.8) 31 (42.5) 0.007 0.003
Dyslipidemia 38 (11.2) 4 (5.5) 0.19 0.61
Previous Stroke 59 (17.5) 22 (30.1) 0.01 0.007
Pneumonia (anamnestic) 43 (12.7) 12 (16.4) 0.40 0.78
Gastric ulcer 52 (15.4) 7 (9.6) 0.20 0.16
Diabetes 44 (13.0) 12 (16.4) 0.44 0.42
Cancer 46 (13.6) 7 (9.6) 0.35 0.41
Table 3  Logistic regression analysis, association between 
certified clinical diagnosis of any type dementia and lympho-
cyte-to-monocyte ratio, adjusted for age and sex, stratifying for 
stroke, hypertension, and obesity (BMI > 25)
LMR No previous 
stroke
279 51 1.02 (1.01–1.03) 0.003
Previous stroke 59 22 1.01 (0.99–1.04) 0.38
No hypertension 136 42 1.03 (1.00–1.05) 0.04
Hypertension 202 31 1.02 (1.01–1.03) 0.008
BMI < 25 179 52 1.04 (1.02–1.06)  < 0.001
BMI ≥ 25 159 21 1.01 (0.99–1.03) 0.07
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directly associated with any type of clinical diagno-
sis of dementia, independent of age, sex, lymphocyte 
count, BMI, stroke, and hypertension. Furthermore, 
higher lymphocyte counts are also associated with 
a clinical diagnosis of dementia, but the strength of 
the association is reduced and no longer statistically 
significant when the logistic model includes also the 
LMR.
Immunosenescence is a decline in the functional 
efficiency of the immune system, which may be 
explained in terms of molecular and cellular mecha-
nisms responsible for inflammatory age-associated 
disorders, and indicated as inflamm-aging [21]. The 
pathogenetic effect of inflamm-aging can be inde-
pendent from the total amount of pro-inflammatory 
mediators, but rather, it could depend on their loca-
tion, and on the type of activated cells [6]. A hallmark 
of individuals with dementia is neuroinflammation, 
an innate immunological response in the nervous 
system [2]; this has been observed to occur in the 
brains of those affected [10]. In the immune patho-
physiological process of dementia, at least two phases 
are assumed to exist: the early preclinical stage with 
a predominantly proinflammatory component, and 
the late clinical stage, characterized by an imbalance 
between innate/adaptive systems [2, 4]. Most of the 
conceptual framework underlying this theoretical 
pathway was derived from animal models or autopsy 
of subjects with preclinical symptoms, but without 
an established diagnosis of dementia [2]. Therefore, 
much research effort is devoted to identify possible 
low cost, and highly efficient, biological markers of 
preclinical dementia, in order to allow a precision 
medicine approach. In the recent past, the importance 
of leukocyte counts and their derived ratios has been 
established [22] in several fields of clinical medicine, 
as markers of disease progression, predictors of out-
comes, and even of cognitive impairment after acute 
ischemic stroke [23].
In this study, LMR was associated with preva-
lent diagnosis of dementia, only in subjects without 
stroke, whereas this association was not present in the 
group of subjects who had a stroke. In those subjects 
affected only by dementia, the increase in the LMR 
was sustained by the lymphocyte absolute count 
increase, and a contextual monocyte absolute count 
decrease, clearly showing an imbalance between 
innate ad adaptive immunity. Conversely, in subjects 
with a history of stroke, and in those also diagnosed 
with dementia, only a decrease in monocyte abso-
lute count was observed. In previous studies, LMR 
was reported to be a marker of clinical progression 
[24], disease complications and poor outcome [25] in 
acute ischemic and hemorrhagic stroke, but not in the 
chronic phase of the disease. The temporal trend of 
immune cells infiltrating the brain, and their periph-
eral variations have been recently reviewed [26], 
even if studied mostly in animal models. Neutro-
phils, monocytes, and lymphocytes increased in the 






























Fig. 1  Lymphocyte and monocyte absolute counts, and lymphocyte-to-monocyte ratio (LMR), according to dementia and stroke. *p 
value < 0.05; **p value < 0.01; ***p value < 0.001
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found locally for 15–30 days after the ischemic event. 
Peripherally, after an ischemic stroke, there is an 
exponential increase in the neutrophil count together 
with a decrease in the lymphocyte count [27]. What 
happens in the long-lasting phase after the stroke is 
less known. In a retrospective study, in stroke patients 
treated with recombinant tissue plasminogen activa-
tor, increased numbers of circulating monocytes were 
associated with a poorer outcome [28]. In the Mug-
ello study, the localization and the dimension of the 
ischemic lesion, and the age at the stroke event, were 
not assessed, but we might surmise that those robust 
oldest-old survived to stroke thanks to a low mono-
cyte absolute count.
To the best of our knowledge, this is the first report 
describing the association between lymphocyte-to-
monocyte ratio and dementia in a cohort of oldest-
old. The probable/possible relative increase of the 
adaptive, simultaneous with a probable/possible 
relative reduction of the innate, immune response, 
is amenable to different hypotheses. For instance, it 
may represent an example of adaptative/maladap-
tative immunological response in the pathogenesis 
of dementia [29]. The overstimulated immune sys-
tem, activated perhaps by micro-bleeding and/or Aβ 
plaque formation, may lead to an “immune paraly-
sis” state [30]. Ultimately, the immune system can-
not generate an adequate cellular response [29], with 
increased immunosuppressive activity on inflamma-
tion, targeted to protect neurons, but de facto induc-
ing an increase of Aβ plaque deposition [7]. Alter-
natively, the imbalance between innate/adaptive 
immunity in this cohort of nonagenarians may just 
be due to the aging leukocytes’ endowment (immu-
nobiography), to be considered independently from 
dementia [31]. Lastly, the Mugello study enrolled 
a “successful and robust” cohort of nonagenarians, 
since they were long-survivors. Probably, as for cen-
tenarians, they may show reduced inflamm-aging and 
slower immunosenescence that enable them to reach 
this extreme phase of life [32]. This hypothesis could 
explain why subjects with a diagnosis of dementia 
showed a less inflamed phenotype. Indeed, it is dif-
ficult to suggest the leukocytes ratios as helpful in the 
early diagnosis of dementia, since they may reflect 
the “later immunological clinical phase” of dementia, 
with a reduction in adaptive immune activity [4].
Two of the most important factors (hypertension 
and overweight) classically associated with aging, 
inflammation, and cardiovascular events apparently 
do not affect the association between leukocytes 
ratio and dementia. Interestingly, higher lymphocyte 
counts are associated with a clinical diagnosis of 
dementia. Since the analysis is adjusted for age and 
sex, this association cannot be justified by chrono-
logical age or sex dimorphism [33]. In the multivari-
ate models, the differences in lymphocyte numbers 
between the two groups were no longer present. We 
did not find lymphopenia to be a common feature 
in our sample. This is at variance with the reported 
lymphopenia in degenerative dementia, or with the 
similar lymphocyte counts observed in Alzheimer’s 
disease patients and controls [34]. However, our data 
refer to a free-living population of nonagenarians, 
which may result in a selection of dementia cases.
Strengths and limitations
The present study has several strengths and limita-
tions that deserve comments. The Mugello study 
offers an opportunity to investigate the association 
between blood peripheral cell-count ratios and clini-
cal diagnosis of dementia, in a cohort of oldest-old 
representative of the Italian general population. Since 
leukocyte-ratios integrate information from differ-
ent cell types, they have higher informative content 
than single inflammatory biomarkers, and their use is 
potentially advantageous [35]. Moreover, the relation-
ship between LMR and cognitive status in nonagenar-
ians has not been previously investigated.
As a limitation, our cross-sectional study natu-
rally precludes the possibility to establish a causal 
relationship of the associations, and to assign a prog-
nostic value to LMR in dementia progression. As a 
further limitation, the diagnosis of dementia in our 
study is clinical, and retrospective; thus, no attempt 
was made to classify the subtype or disease stage. 
Furthermore, subjects in the asymptomatic stage or 
affected by mild cognitive impairment were not iden-
tified. Results reported in this study do not uniquely 
support an inflammatory paradigm for the develop-
ment of dementia, since the association of leukocyte-
derived ratios might reflect a subclinical response to 
infections, which are a highly probable and frequent 
event in frail and compromised subjects [36]. Finally, 
several confounding factors, such as the ApoE 
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genotype, significantly affecting dementia risk, were 
not explored in this study.
Conclusion
In a population of free-living nonagenarians, higher 
LMR was associated with late-life any type demen-
tia. However, this association was no longer observed 
in participants with dementia who had a previous 
stroke. The hypothesis that LMR is associated to any 
type dementia must be further verified. Since LMR is 
a low-cost and easily accessible index, longitudinal 
studies of its use as a biomarker for the diagnosis of 
neurodegenerative dementia in different stages should 
be planned.
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